New IVIG treatment aims to boost platelets in bleeding disorder

NCT ID NCT06962631

Recruiting now Disease control Sponsor: On Pharma Importadora, Exportadora e Distribuidora de Medicamentos LTDA. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether V-IMMUNE, a human immunoglobulin given through a vein, can safely raise platelet counts in people with immune thrombocytopenia (ITP). About 31 adults and children aged 1 year and older with very low platelets will receive two daily infusions. The main goal is to see if platelets reach a safe level within 9 days.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: V-IMMUNE (human immunoglobulin given intravenously)
What this could lead to: If successful, this could provide a safe and effective treatment option to quickly raise platelet counts and reduce bleeding risk in people with immune thrombocytopenia.
What could go wrong: This is a small, single-group study comparing results to historical data, not a placebo-controlled trial. The treatment may not work for everyone and carries risks like infusion reactions or blood clots.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IMMUNE THROMBOCYTOPENIA (ITP) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Purpura, Thrombocytopenic, Idiopathic thrombocytopenia due to immune destruction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IMMUNE THROMBOCYTOPENIA (ITP)

Contacts and locations

Locations

IMIP Instituto de Medicina Integral Professor Fernando Figueira
NOT_YET_RECRUITING

Recife, Pernambuco, 50070-902, Brazil
Santa Casa de Misericórida de São Paulo
RECRUITING

São Paulo, São Paulo, 01221020, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.